Pfizer Cuts 2025 Revenue Guidance to About $62.0 Billion, Sets 2026 EPS at $2.80-$3.00
Pfizer lowered its full-year 2025 revenue guidance to approximately $62.0 billion from $61.0 to $64.0 billion, while reaffirming its 2025 adjusted diluted EPS guidance of $3.00 to $3.15. The company also issued 2026 guidance calling for revenue of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00, below the 2025 EPS range, citing a higher expected tax rate and about $1.5 billion of revenue loss from loss of exclusivity.
- 2025 revenue guidance revised to approximately $62.0 billion from $61.0 to $64.0 billion; 2025 adjusted diluted EPS guidance of $3.00 to $3.15 reaffirmed
- 2026 adjusted diluted EPS guidance of $2.80 to $3.00, with an effective tax rate of approximately 15% versus approximately 11% in 2025
- 2026 revenue guidance of $59.5 to $62.5 billion includes about $1.5 billion lower COVID-19 product revenue and about $1.5 billion negative impact from loss of exclusivity
- 2026 adjusted SI&A and R&D expenses combined expected at $23.0 to $25.0 billion; guidance assumes no share repurchases in 2025 or 2026